Signe Plāte

Suggest Changes
Learn More
BACKGROUND Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy(More)
BACKGROUND This randomized phase II study investigated first-line chemotherapy plus cetuximab administered every second week in KRAS wild-type metastatic colorectal cancer. PATIENTS AND METHODS(More)
494 Background: FOLFOX4 + q1w cetuximab is a standard 1st-line regimen in KRAS wt mCRC. This trial evaluated FOLFOX4 + q1w cetuximab (Arm A) and FOLFOX4 + q2w cetuximab (Arm B) as 1st-line therapy in(More)